Investor Alert: Takeover of Covance Inc. (NYSE:CVD) under Investigation | Business, Financial Markets | GroundReport.com – Latest World News & Opinions
Theannounces that an investigation on behalf of , who currently hold shares of Covance Inc. ( :CVD), was initiated concerning whether the of Covance Inc. by Corporation of America for a approximately $105.12 per share is unfair to NYSE:CVD stockholders.
Those who are current investors in Covance Inc. shares have certain options and should contact theFoundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego
The SEC should have stopped LabCorp’s growth before its purchase of Orchid Cellmark, seeing as LabCorp was disinterested in whether Orchid Cellmark had failed to report the suspect condition of evidence received for DNA testing … at least twice.
A cornered market on the prices of DNA testing isn’t in the public’s interest. Especially a cornered, irresponsible market.
The SEC believes otherwise, obviously. They apparently like corporations that are too big to hold accountable, even for life and death matters like the affordability and reliability of DNA testing of crime scene evidence.
Taxpayers have spent big, big bucks through federal grants to get rid of the backlog on DNA testing of rape kits – and those backlogs never get cleared up, even though automation has cut the costs of performing DNA tests. This has rape kits routinely tested after the state of limitations has expired on the rapes. Serial rapists are likely to step up their game, and become serial killers.
Congressional Oversight, has allowed the SEC to see itself as self-employed, with no obligation to the public at large, or to shareholders. To my knowledge, six law firms as well as the Shareholders Foundation have now stepped up to addreess LabCorp’s takeover of Covance.
Unless all seven parties push to break LabCorp into bits small enough to hold accountable, ensuring public safety via rapid, reliable DNA testing will remain impossible.